Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0U9TM
|
||||
| Former ID |
DNC001141
|
||||
| Drug Name |
Ponalrestat
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Gout [ICD9: 274.00274.1274.8274.9; ICD10:M10] | Discontinued in Phase 3 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C17H12BrFN2O3
|
||||
| Canonical SMILES |
C1=CC=C2C(=C1)C(=NN(C2=O)CC3=C(C=C(C=C3)Br)F)CC(=O)O
|
||||
| InChI |
1S/C17H12BrFN2O3/c18-11-6-5-10(14(19)7-11)9-21-17(24)13-4-2-1-3-12(13)15(20-21)8-16(22)23/h1-7H,8-9H2,(H,22,23)
|
||||
| InChIKey |
LKBFFDOJUKLQNY-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 72702-95-5
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
5616278, 8153244, 11113738, 11120263, 11120751, 11121239, 11342114, 11362297, 11364377, 11366939, 11369501, 11371896, 11374993, 11377663, 11485129, 11487699, 11489283, 11490863, 11493002, 11495297, 12013115, 14829960, 17397894, 26680549, 29224333, 47364952, 50065127, 53530998, 57322692, 85789490, 85789665, 103123627, 103165638, 103922759, 104308777, 117389119, 124637034, 124886948, 128500409, 134339117, 134340376, 135011929, 135698020, 135727686, 137122051, 139060527, 142773112, 144204481, 162022632, 162655628
|
||||
| Target and Pathway | |||||
| Target(s) | Aldose reductase | Target Info | Inhibitor | [2] | |
| BioCyc Pathway | Methylglyoxal degradation III | ||||
| Acetone degradation I (to methylglyoxal) | |||||
| KEGG Pathway | Pentose and glucuronate interconversions | ||||
| Fructose and mannose metabolism | |||||
| Galactose metabolism | |||||
| Glycerolipid metabolism | |||||
| Metabolic pathways | |||||
| NetPath Pathway | IL1 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | |||||
| PathWhiz Pathway | Fructose and Mannose Degradation | ||||
| Pyruvate Metabolism | |||||
| Pterine Biosynthesis | |||||
| Glycerolipid Metabolism | |||||
| Galactose Metabolism | |||||
| WikiPathways | Metapathway biotransformation | ||||
| Polyol Pathway | |||||
| Metabolism of steroid hormones and vitamin D | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000017) | ||||
| REF 2 | Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome induced by colon26 adenocarcinoma in mice. Anticancer Res. 1999 Sep-Oct;19(5B):4105-11. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.